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Abstract Pulmonary arterial hypertension (PAH) is a pro-
gressive and life-threatening disease. Understanding of PAH
prevalence remains limited, but PAH has been reported as a
frequent complication in connective tissue diseases. This
study estimated prevalence of PAH in patients with connec-
tive tissue diseases and prevalence of idiopathic PAH using a
systematic review of the literature. We searched PubMed
through May 19, 2012 for all studies on prevalence of PAH
in patients with connective tissue diseases or prevalence of
idiopathic PAH. To be included, studies had to be in English,
have humans as subjects, and determine prevalence within a
time interval of up to 2 years. Studies only investigating
pediatric patients were excluded. Pooled prevalence esti-
mates were calculated. Twenty studies were identified in
the review. Seventeen of the 20 studies reported prevalence
of PAH in connective tissue diseases and three reported
prevalence of idiopathic PAH. The pooled prevalence esti-
mate of idiopathic PAH was 12 cases per million population
(95 % CI 5 cases per million to 22 cases per million) with
estimates ranging from 5.9 cases per million population to 25
cases per million population. The pooled prevalence estimate
of PAH in patients with connective tissue diseases was 13 %
(95 % CI, 9.18 % to 18.16 %) with reported estimates
ranging from 2.8 % to 32 %. Prevalence of PAH in patients
with connective tissue diseases was substantially higher than
that of idiopathic PAH based on pooled prevalence estimates.
Comparisons of PAH prevalence in persons with con-
nective tissue disease and idiopathic PAH using a large ob-
servational study would be helpful in better assessing relative
prevalence.
Keywords Connective tissue diseases . Prevalence .
Pulmonary hypertension . Review
Introduction
Pulmonary hypertension is defined as a mean pulmonary
artery pressure of at least 25 mmHg at rest [1]. One subgroup
of pulmonary hypertension, pulmonary arterial hypertension
(PAH), is a progressive and life-threatening disease charac-
terized by elevation of mean pulmonary arterial pressure and
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pulmonary vascular resistance, leading to right heart failure
and death [2].
PAH is an important complication of connective tissue
diseases, a group of disorders characterized by vascular
injury, autoimmunity, tissue inflammation, and organ
dysfunction [3, 4] including systemic sclerosis [5], sys-
temic lupus erythematosus [6], mixed connective tissue dis-
eases [7, 8], and to a lesser extent, rheumatoid arthritis,
polymyositis/dermatomyositis, and Sjogren’s syndrome [9].
Data on prevalence of PAH in patients with connective
tissue diseases remain limited due to rare occurrence of the
disease [10–12] and challenges to obtain high-quality data
appropriate for prevalence estimation [9]. This systematic
literature review was conducted to estimate prevalence of
PAH in patients with connective tissue diseases and preva-
lence of idiopathic pulmonary arterial hypertension based on
data from the literature.
Materials and methods
Literature search strategy
Publications examining prevalence of idiopathic pulmo-
nary arterial hypertension and prevalence of pulmonary
arterial hypertension in patients with connective tissue
diseases were identified by a PubMed search specifying
publication date from inception through May 19, 2012.
To identify studies estimating prevalence of idiopathic pulmo-
nary arterial hypertension, a search combined the medical
subject heading “Hypertension, Pulmonary/epidemiology”
or supplementary concept “Pulmonary arterial hypertension”
with the term idiopathic was used, and the medical subject
heading “Hypertension, Pulmonary” combined with any of
the terms “epidemiology,” “prevalence,” “frequency,”
“occurrence,” or “incidence”, and with the term idio-
pathic was also used. In addition, a search restricted to
studies, in which the medical subject heading "Hyper-
tension, Pulmonary/epidemiology” was identified as the
main topic was conducted. To identify studies, which
estimated prevalence of PAH in patients with connective
tissue diseases, a search combined the medical subject
headings “Hypertension, Pulmonary,” or supplementary
concept “Pulmonary arterial hypertension,” or term “pulmo-
nary arterial hypertension,” with the medical subject heading
“Connective tissue disease,” or either of the terms “connective
tissue diseases,” “scleroderma,” “systemic sclerosis,” “lupus,”
“mixed connective tissue disease,” “rheumatoid arthritis,”
“Sjogren's,” “Sjogren, ” “polymyositis,” or “dermatomyosi-
tis”was conducted. A search with the medical subject heading
“Prevalence” or medical subheading “epidemiology” or terms
including “prevalence,” “frequency,” “occurrence,” or “inci-
dence” combined with the above search was also conducted.
Reference lists of articles obtained from the results in PubMed
search were also examined to identity articles.
Inclusion and exclusion criteria
All the titles and abstracts of the results in searches were
reviewed to determine if the objectives of the studies were
relevant to prevalence of idiopathic pulmonary arterial hy-
pertension or prevalence of PAH in patients with connective
tissue diseases. To be included, articles had to be written in
English and have human subjects. Studies were required to
have reported a PAH prevalence in patients with connective
tissue diseases or an idiopathic pulmonary arterial hyperten-
sion prevalence. Studies were required to report prevalence
for an interval less than or equal to 2 years. Articles only
investigating pediatric patients, i.e., with age less than 18-
years old were excluded. Articles which only reviewed prior
studies were excluded, since the original studies were exam-
ined in this review. Only studies with full text in English
were included. Case reports, letters to the editor, and edito-
rials were excluded.
Data analysis
Estimates of prevalence of PAH in patients with each type of
connective tissue disease including systemic sclerosis, sys-
temic lupus erythematosus, mixed connective tissue dis-
eases, and rheumatoid arthritis and estimates of the preva-
lence of idiopathic pulmonary arterial hypertension were
extracted from reviewed articles. A summary table including
author, title, journal, published year, study period, objec-
tives, data source, disease definition, country in which the
study was conducted, and main findings of each study was
created (Table 1). To estimate the prevalence of idiopathic
pulmonary arterial hypertension and prevalence of PAH in
patients with each type of connective tissue disease for which
more than one study was found, proportion meta-analyses
were conducted.
The StatsDirect statistical software package version
2.7.8b (StatsDirect Ltd, Cheshire, UK) was used to conduct
proportion meta-analysis. The I2 statistic in proportion meta-
analysis, which describes the percentage of variation across
studies in the outcome of interest due to heterogeneity rather
than chance was used to decide whether a random-effects or
fixed-effects model was appropriate for the analysis [13]. If
the 95 % confidence interval on I2 did not contain 0 %, it
indicated that use of the random effects model was appro-
priate. Otherwise, the fixed-effects model should be used.
The DerSimonian-Laird random-effects pooling method
[14] was used in proportion meta-analysis if a random-
effects model was chosen. The 95 % confidence intervals
for the pooled prevalence estimate of idiopathic pulmonary
arterial hypertension and for the pooled prevalence estimate
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of PAH in patients with connective tissue diseases, in pa-
tients with systemic sclerosis, in patients with systemic lupus
erythematosus, and in patients with arthritis rheumatoid were
calculated.
Although echocardiography is often used to initially di-
agnose PAH, right heart catheterization is necessary to con-
firm diagnosis [15]. Since PAH diagnosis based on echocar-
diography does not have the specificity of diagnosis by
catheterization and therefore may inflate prevalence esti-
mates [16], subgroup analysis was conducted, when possi-
ble, based on groups organized by whether right heart cath-
eterization was used for confirmation of PAH diagnosis to
assess the effect of not confirming diagnosis by catheterization
on prevalence estimates.
Results
Articles on PAH prevalence
Three hundred one studies were screened to decide if inclu-
sion criteria were met for articles reporting PAH prevalence
in patients with connective tissue diseases. A total of 284
studies were excluded, 192 because they did not report
prevalence of PAH in patients with connective tissue dis-
eases, 34 only mentioned prevalence of PAH in patients with
connective tissue disease reported in prior studies, and 24
reported PAH prevalence in patients with connective tissue
diseases based on a study interval longer than 2 years. Ten
excluded studies did not specify a study period during which
PAH prevalence in patients with connective tissue was report-
ed. Four articles were editorials; 14 were case reports, and four
were letters or correspondence. Two were excluded because
they reported PAH prevalence in patients with systemic scle-
rosis using the same data bases as other included studies [17,
18]. The remaining 17 articles were used in the meta-analysis
of PAH prevalence in patients with connective tissue diseases.
Six hundred ninety-six articles were screened to identify
articles which reported prevalence of idiopathic PAH. Ninety-
six of the 696 articles also appeared in the search results for
PAH prevalence in connective tissue diseases. A total of 693
articles were excluded, 604 because they did not report prev-
alence of idiopathic PAH, three reported prevalence of idio-
pathic PAH among pediatric patients only, and four articles
only reported prevalence from prior studies. Twenty-eight
excluded articles were letters; 25 were case reports; 29 were
editorials. The remaining three articles were used in the meta-
analysis of idiopathic pulmonary arterial hypertension.
A summary of selected studies reporting prevalence of
PAH in patients with connective tissue diseases and preva-
lence of idiopathic pulmonary arterial hypertension is shown
in Table 1. No studies were found that estimated prevalence
of PAH in patients with connective tissue diseases in general.
After exclusion, a total of 20 studies remained that met
inclusion criteria for this study. Seventeen of the 20 studies
reported prevalence of PAH in connective tissue diseases,
and three reported prevalence of idiopathic pulmonary arte-
rial hypertension. Twelve of the 17 studies reported preva-
lence of PAH in patients with systemic sclerosis [19–30].
Two of the 17 studies reported prevalence of PAH in patients
with systemic lupus erythematosus [31, 32], two reported prev-
alence of PAH in patients with rheumatoid arthritis [33, 34], and
one reported prevalence of PAH in a combined patients group
with systemic sclerosis and mixed connective tissue diseases
[35]. No studies were found that determined prevalence of PAH
in patients with polymyositis/dermatomyositis or Sjogren’s
syndrome.
Prevalence of idiopathic pulmonary arterial hypertension
Individual studies reported estimated prevalence of idiopath-
ic pulmonary arterial hypertension ranging from 5.9 cases
per million population to 25 cases per million population
(Fig. 1). Based on the I2 statistic, 97.6 % (95 % CI, 96 % to
98.3 %), the random effects model was used to estimate
prevalence of idiopathic pulmonary arterial hypertension.
The pooled prevalence estimate of idiopathic pulmonary
arterial hypertension was 12 cases per million population
(95 % CI, five cases per million population to 22 cases per
million population). The Harboard test suggested that there
was no bias across studies in prevalence of idiopathic pul-
monary arterial hypertension (Table 2).
Subgroup analysis by whether right heart catheterization
was used for diagnosis
Among three studies reporting prevalence of idiopathic pul-
monary arterial hypertension [10–12], diagnosis of PAH was
confirmed by right heart catheterization in one study by
Humbert et al. The other two studies did not use right heart
catheterization for confirmation of all PAH diagnosis, al-
though one of the two estimated prevalence in a cohort in
which 72 % of patients underwent right heart catheterization
[12]. The other study used International Classification of
Diseases to identify idiopathic pulmonary arterial hyperten-
sion based on national hospitalization registry data for Scot-
land [10]. A subgroup proportion meta-analysis was
conducted based on the two studies in which right heart
catheterization was not used to confirm all diagnoses of
PAH, since use of only echocardiograph for diagnosis may
inflate prevalence estimates.
It was not possible to obtain an I2 statistic since there were
only two studies in the subgroup, so analyses using both
random-effects model and fixed-effects model were
conducted. Cochran’s Q, another statistic to measure hetero-
geneity, has low power as a comprehensive test of
1524 Clin Rheumatol (2013) 32:1519–1531
heterogeneity [36], especially when the number of studies is
small. Even with this low-power Cochran’sQwas 35.34 (P<
0.0001), which suggested a random-effects model should be
used in pooled prevalence estimation (Table 2). Bias assess-
ment was not available due to having only two studies. The
pooled idiopathic pulmonary arterial hypertension preva-
lence in the two studies without diagnosis confirmation via
heart catheterization was 16 cases per million population
(95 % CI, four cases per million population to 36 cases per
million population) which was higher than the idiopathic
pulmonary arterial hypertension prevalence estimate of 5.9
cases per million population in the one study in which right
heart catheterization was used (Fig. 1).
Prevalence of PAH with connective tissue diseases
Among the 17 studies that reported prevalence of PAH in
patients with connective tissue diseases, estimates ranged
0.00E+00 1.00E-05 2.00E-05 3.00E-05 4.00E-05
combined 15.8 cases per million (3.85 cases per million, 35.9 cases per million)
Peacock et al. 25 cases per million (19.8 cases per million, 31.1 cases per million)
Tueller et al. 8.67 cases per million (6.47 cases per million, 11.4 cases per million)
proportion (95% confidence interval)
Legend: : prevalence estimate in selected study (relative size of box stands for relative weight)
◊: Pooled prevalence estimate
Proportion meta-analysis of prevalence of idiopathic PAH not diagnosed by right heart catheterization [random effects]
0.00E+00 8.00E-06 1.60E-05 2.40E-05 3.20E-05
combined 11.9 cases per million (4.64 cases per million, 22.4 cases per million)
Peacock et al. 25 cases per million (19.8 cases per million, 31.1 cases per million)
Tueller et al. 8.67 cases per million (6.47 cases per million, 11.4 cases per million)
Humbert et al. 5.91 cases per million (5.22 cases per million, 6.66 cases per million)
proportion (95% confidence interval)
Proportion meta-analysis of prevalence of idiopathic PAH regardless of whether right heart catheterization was 
used to confirm diagnosis of PAH [random effects]
Legend: : prevalence estimate in selected study (relative size of box stands for relative weight)
◊: Pooled prevalence estimate
Fig. 1 Proportion meta-analysis of prevalence of idiopathic pulmonary arterial hypertension for all groups and for subgroup not diagnosed by right
heart catheterization
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from 2.8 % to 32 %. Based on the I2 statistic, 96.8 % (95 %
CI, 96.2 % to 97.3 %), a random-effects model was used to
estimate PAH prevalence in patients with connective tissue
diseases (Table 2). The pooled prevalence estimate of PAH in
patients with connective tissue diseases was 13 % (95 % CI,
9.18 % to 18.16 %) (Fig. 2).
Systemic sclerosis
Twelve individual studies reported PAH prevalence ranging
from 3.6 % to 32% in patients with systemic sclerosis. Based
on the I2 statistic, 95.5 % (95 % CI, 94.1 % to 96.4 %), a
random-effects model was used to estimate the prevalence of
PAH in patients with systemic sclerosis (Table 2). The
pooled prevalence estimate of PAH in patients with systemic
sclerosis was 13 % (95 % CI, 8.96 % to 17.87 %) (Fig. 3)
Systemic lupus erythematosus
Two studies reported prevalence of PAH ranging from 2.8 %
to 4.2 % in patients with systemic lupus erythematosus. An I2
statistic could not be obtained since only two studies were
included. Cochran’s Q was 1.43 (P=0.2313). Since
Cochran’s Q test has low power to test heterogeneity when
the number of studies is small, pooled prevalence of PAH in
lupus based on both fixed-effect and random-effect models
were calculated. The pooled prevalence estimate of PAH in
patients with lupus was 3.34 % (95 % CI, 2.10%to 4.86 %)
based on random-effects model and was 3.24 % (95 % CI,
2.26 % to 4.38 %) based on a fixed-effect model (Fig. 3)
Rheumatoid arthritis
Two studies reported prevalence of PAH in patients with
rheumatoid arthritis ranging from 21 % to 27.5 %. An
I2statistic could not be obtained since only two studies were
included. Both fixed-effect and random-effect models were
used. Pooled prevalence of PAH in patients with arthritis
rheumatoid was 22.3 % (95 % CI, 16.63 % to 28.48 %)
based on both fixed-effect and random-effect models
(Fig. 3). No bias indicators were available due to having
only two studies. In both studies, PAH diagnosis was based
on echocardiography. One study reported PAH prevalence in
a patient group with systemic sclerosis and mixed connective
tissue disease in which some diagnoses were confirmed with
catheterization and some were not, at 26.7 % [35].
Subgroup analysis by whether right heart catheterization
was used for diagnosis
Among studies reporting prevalence of PAH in patients with
connective tissue diseases, only the studies focusing on
systemic sclerosis populations included a mix of studies that
used right heart catheterization to confirm diagnosis and
studies that only used echocardiograph for PAH diagnosis.
That mix of studies allowed subgroup analysis of prevalence
Table 2 Results of non-combinability test and bias assessment for prevalence estimation
Non-combinability Bias assessment P value Confidence interval
I2 Cochran Q Egger Harbord
Idiopathic pulmonary arterial hypertension 97.6 % 96 % to 98.3 % (95 %)
12.11 0.3457 −49.67 to 73.90 (92.5 %)
Not diagnosed by right heart catheterization 35.34 <0.0001
PAH in connective tissue diseases 96.8 % 96.2 % to 97.3 % (95 %)
6.04 0.0031 2.38 to 9.69 (95 %)
3.37 0.3225 −2.93 to 9.67 (92.5 %)
PAH in systemic sclerosis 95.5 % 94.1 % to 96.4 % (95 %)
5.34 0.0121 1.45 to 9.23 (95 %)
4.07 0.2382 −2.37 to 10.51 (92.5 %)
Diagnosed by echocardiography 79.6 % 50.9 % to 88.5 % (95 %)
−1.62 0.5386 −7.91 to 4.68 (95 %)
−1.66 0.439 −6.09 to 2.77 (92.5 %)
Diagnosed by right heart catheterization 92 % 84.4 % to 95 % (95 %)
6.03 0.1071 −2.39 to 14.45(95 %)
5.43 0.3774 −8.66 to 19.53 (92.5 %)
PAH in lupus 1.43 0.2313
PAH in rheumatoid arthritis 0.93 0.3351
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of PAH by whether right heart catheterization was used to
confirm diagnosis of PAH. Five out of 12 studies reporting
prevalence of PAH in systemic sclerosis were based on data
with diagnosis confirmed by right heart catheterization
[19–23], and seven were based on data from PAH patients
diagnosed by echocardiography [24–30].
Based on the I2 statistic, 92 % (95 % CI, 84.4 % to 95 %),
the random-effects model was used for proportion meta-
analysis, for estimates of prevalence of PAH among persons
with systemic sclerosis with PAH diagnosis confirmed by right
heart catheterization (Table 2). The pooled prevalence estimate
of PAH diagnosed by right heart catheterization in patients with
systemic sclerosis was 8.2 % (95 % CI, 5.2 % to 11.8 %)
(Fig. 4). The Harbord test suggested that there was no bias
across studies in prevalence of PAH diagnosed by right heart
catheterization in patients with systemic sclerosis (Table 2).
Based on the I2 statistic, 79.6 % (95 % CI: 50.9 % to
88.5 %) (Table 2), a random-effects model was used to
estimate the prevalence of PAH diagnosed by echocardiog-
raphy without catheterization confirmation in patients with
systemic sclerosis. The pooled prevalence estimate of PAH
diagnosed without catheterization among persons with
systemic sclerosis was 18 % (95 % CI, 14 % to 23 %)
(Fig. 4). The Harbord test suggested that there was no bias
across selected studies estimating prevalence of PAH diag-
nosed by echocardiography in patients with systemic sclero-
sis in meta-analysis (Table 2). This higher prevalence esti-
mate (18 %) among studies in systemic sclerosis populations
that did not use heart catheterization for PAH diagnosis
confirmation as compared with those that did confirm diag-
nosis with catheterization (8.2 %) likely reflects a tendency
for inflation of prevalence estimates when catheterization
diagnosis confirmation was not used.
Discussion
The estimate of idiopathic pulmonary arterial hypertension
prevalence was 12 cases per million population (95 % CI,
five cases per million population to 22 cases per million
population), and the estimate of PAH prevalence in patients
with connective tissue diseases was 13 % (95 % CI, 9.18 %
to 18.16 %) in meta-analysis. These findings confirm that the
prevalence of PAH in patients with connective tissue
Fig. 2 Proportion meta-
analysis of prevalence of PAH
in patients with connective
tissue diseases
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diseases appears much higher than the prevalence of idio-
pathic pulmonary arterial hypertension.
Current published PAH prevalence studies in patients
with connective tissue diseases used inconsistent criteria
for identifying PAH. With better understanding of the dis-
ease, there have been a series of changes in definition of PAH
[37–39]. A resting mean pulmonary arterial pressure greater
than or equal to 25 mm Hg and a pulmonary capillary wedge
pressure less than 15 mm Hg [38] were proposed at the
Fourth World Symposium on Pulmonary Hypertension in
2008. Some definitions also include pulmonary vascular
resistance greater than 2 or 3 mm Hg/l/min [15, 38, 40]. The
use of various definitions of PAH for diagnosis of PAH
impairs comparisons among studies reporting prevalence.
Echocardiography is used to screen for PAH, but right heart
catheterization is the gold standard to confirm diagnosis of
PAH [40]. Prior studies have shown that discordance exists
between estimation of pulmonary hemodynamics in echocar-
diography and estimation directly by invasive catheterization
techniques [15]. PAH diagnosis based on echocardiography
does not have the specificity of diagnosis by catheterization
[16] and may inflate estimates of the prevalence of PAH.
For studies in systemic sclerosis, when right heart catheter-
ization was not used to confirm PAH diagnosis, the PAH
prevalence estimate was 18 % (95 % CI, 14 % to 23 %). When
right heart catheterization was used, PAH prevalence estimate
in systemic sclerosis was 8.2% (95%CI, 5.2% to 11.8%). The
higher prevalence estimates when only echocardiography was
used is consistent with prior evidence that PAH diagnosis by
echocardiography may inflate PAH prevalence estimate [16].
Two registry studies focusing on patients with PAH asso-
ciated with connective tissue diseases were found in the
literature search. Condliffe et al. reported prevalence of PAH
associated with connective tissue diseases in a UK population,
on June 31, 2006, of 4.23 per million or 0.000423 % [41].
Chung et al. reported percentages of patients with PAH asso-
ciated with systemic sclerosis, lupus, mixed CTD, and rheu-
matoid arthritis among all known PAH–CTD patients,
Legend: : study prevalence estimate (relative size of box equals relative weight)
pooled prevalence estimate
0.1 0.2 0.3 0.4 0.5
combined 0.22 (0.17, 0.28)
Keser et al. 0.28 (0.15, 0.44)
Dawson et al. 0.21 (0.14, 0.28)
proportion (95% confidence interval)
Proportion meta-analysis of prevalence of PAH in patients with rheumatoid 
arthritis [random effects]
Legend: : study prevalence estimate (relative size of box equals relative weight)
pooled prevalence estimate
0.00 0.02 0.04 0.06 0.08
combined 0.03 (0.02, 0.05)
Prabu et al. 0.04 (0.02, 0.07)
Pan et al. 0.03 (0.02, 0.04)
proportion (95% confidence interval)
Proportion meta-analysis of prevalence of PAH in patients with lupus 
[random effects]
Legend: : study prevalence estimate (relative size of box equals relative weight)
pooled prevalence estimate
0.00 0.02 0.04 0.06 0.08
combined 0.03 (0.02, 0.04)
Prabu et al. 0.04 (0.02, 0.07)
Pan et al. 0.03 (0.02, 0.04)
proportion (95% confidence interval)
Proportion meta-analysis of prevalence of PAH in patients with lupus [fixed 
effects]
Legend: : study prevalence estimate (relative size of box equals relative weight)
pooled prevalence estimate
0.0 0.2 0.4 0.6
combined 0.13 (0.09, 0.18)
Yamane et al. 0.11 (0.06, 0.18)
Chang et al. 0.19 (0.16, 0.23)
Gindzienska et al. 0.06 (0.01, 0.16)
Pope et al. 0.23 (0.20, 0.27)
Kumar et al. 0.32 (0.23, 0.42)
Coral-Alvarado et al. 0.17 (0.14, 0.22)
de Azevedo et al. 0.14 (0.06, 0.26)
Phung et al. 0.13 (0.09, 0.19)
Vonk et al. 0.10 (0.08, 0.12)
Avouac et al. 0.04 (0.03, 0.05)
Hachulla et al. 0.09 (0.06, 0.11)
0.08 (0.06, 0.10)
proportion (95% confidence interval)
Proportion meta-analysis of prevalence of PAH in patients with systemic 
sclerosis [random effects]
Hachulla et al.
Fig. 3 Proportion meta-analysis of prevalence of PAH in patients with systemic sclerosis, lupus, and rheumatoid arthritis
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respectively [42]. However, the focus of our analysis was to
estimate PAH prevalence in CTD populations.
In studies in which PAH prevalence was estimated in
patients with rheumatoid arthritis or in patients with systemic
lupus erythematosus, PAH was not confirmed by right heart
catheterization among all patients. Therefore, the estimates
of PAH prevalence in patients with rheumatoid arthritis or in
patients with systemic lupus erythematosus may be inflated
and questionable.
Wigley and colleagues [35] estimated PAH prevalence of
26.7 % among patients with systemic sclerosis or mixed
connective tissue disease in community-based rheumatology
practices. Since less severe cases may be more likely to be
seen in such setting as compared with tertiary centers, lack of
confirmation of PAH diagnosis by right heart catheterization
for many of the patients in their study may have been
particularly likely to inflate the PAH prevalence estimate
such that the estimate may be questionable.
Limitations
A limitation in the current study was that not all of the
selected studies defined PAH using the definition of a mean
pulmonary arterial pressure greater than 25 mm Hg and
Fig. 4 Proportion meta-
analysis of prevalence of PAH
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pulmonary capillary wedge pressure less than 15 mm Hg.
Most of the studies did not require pulmonary capillary
wedge pressure less than 15 mm Hg, and most selected
studies did not use right heart catheterization to confirm
diagnosis of PAH.
Conclusions
Prevalence of PAH in patients with connective tissue dis-
eases was substantially higher than that of idiopathic pulmo-
nary arterial hypertension based on pooled prevalence esti-
mates. Comparisons of PAH prevalence in persons with
connective tissue disease and idiopathic pulmonary arterial
hypertension using a large observational study would be
helpful in better assessing relative prevalence. Nevertheless,
the current finding underscores the need for monitoring for
PAH in patients with connective tissue disease.
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